Alnylam Pharmaceuticals (ALNY) Cash from Investing Activities (2009 - 2026)

Alnylam Pharmaceuticals' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$25.5 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 122.45% year-over-year to -$25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $297.0 million (up 360.14% YoY) and the FY2025 annual result came in at $436.3 million, up 473.44% from the prior year.
• Cash from Investing Activities was -$25.5 million for Q1 2026 at Alnylam Pharmaceuticals, up from -$37.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $501.1 million in Q3 2025 and bottomed at -$240.7 million in Q4 2023.
• A 5-year average of $7.5 million and a median of -$30.2 million in 2024 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 1756.55% in 2025, while the deepest fall reached 516.56% in 2025.
• Alnylam Pharmaceuticals' Cash from Investing Activities stood at -$139.9 million in 2022, then plunged by 72.01% to -$240.7 million in 2023, then soared by 78.01% to -$52.9 million in 2024, then grew by 29.76% to -$37.2 million in 2025, then jumped by 31.28% to -$25.5 million in 2026.
• Business Quant data shows ALNY's Cash from Investing Activities at -$25.5 million in Q1 2026, -$37.2 million in Q4 2025, and $501.1 million in Q3 2025.